Searched for
EUGIA PHARMA SPECIALITIES LTD
Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDAAurobindo Pharma announced its subsidiary Eugia Pharma received a USFDA warning letter. This follows an inspection of their Telangana formu...- Aurobindo Pharma arm gets USFDA nod for generic blood cancer drugAurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, use...
- Aurobindo Pharma shares jump 2% after UK arm secures regulatory approval for cancer drugAurobindo Pharma's stock rose after its subsidiary got approval for a cancer drug. CuraTeQ Biologics received the UK's MHRA approval for Be...
- Aurobindo unit gets USFDA nod for generic cancer drugAurobindo Pharma's subsidiary, Eugia Pharma, gets USFDA nod for cancer drug Pazopanib. The drug treats renal cell carcinoma and soft tissue...
- Eugia Steriles' new injectables facility in Andhra receives its first product approval by FDAAurobindo Pharma Ltd announced that its subsidiary, Eugia Steriles Private Limited, received its first product approval from the US FDA for...
- USFDA pulls up Eugia for manufacturing lapses, data accuracy at Hyderabad plantThe US Food and Drug Administration (USFDA) has issued a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, cit...
- USFDA flags Telangana unit of Aurobindo Pharma armThe letter, issued on August 15, was later made public by the USFDA, which stated that there was failure to ensure the accuracy of data in ...
- Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fallAurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing ...
- Aurobindo may take its injectable unit publicAurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previ...
- Aurobindo Pharma gets USFDA nod for generic antifungal injectionThe approval by the US Food & Drug Administration (USFDA) is for Posaconazole injection of 300 mg/16.7 mL (18 mg/mL), single-dose vial, Aur...
- Aurobindo puts its injectables business on the block, againAurobindo Pharma promoters have begun the process of selling a majority stake in its injectables business, Eugia Pharma Specialities, after...
- Aurobindo Pharma arm gets USFDA nod for Plerixafor injectionAurobindo Pharma said Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hemat...
- Aurobindo Pharma eyes $5-B revenue in 5 yearsAurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialitie...
- Aurobindo Pharma shares rise 3% after subsidiary signs license for generic version of Nilotinib CapsulesShares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with M...
- Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drugIndia's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Me...
- Medley-Cipla deal talks called off over valuation issuesThis is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility ...
- Aurobindo calls off Eugia Pharma Specialities sale on valuation mismatchThe Hyderabad-based promoter family of V Ramprasad Reddy and K Nityanand Reddy currently own 51.8% of Aurobindo, a vertically integrated ph...
- Blackstone closing in on Aurobindo's injectables businessThe keenly contested transaction, now in the final stages of negotiations, pits Blackstone against Baring Private Equity Asia, the only oth...
- Aurobindo Pharma Managing Director N Govindarajan resigns"His resignation was considered and accepted by the board of directors in its meeting today. N Govindarajan will be relieved from the servi...
- Aurobindo Pharma Q4 results: Co reports net profit at Rs 801 croreFor the fiscal ended March this year, the company posted a net profit of Rs 5,333.83 crore. It was Rs 2,843.67 crore in the preceding fisca...
Load More
